GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (GDRX) shares jumped 5.08% in after-hours trading on Monday after announcing a collaboration with Novo Nordisk A/S to offer discounted GLP-1 medications at fixed pricing nationwide. Eligible self-paying patients can access all strengths of Ozempic and Wegovy pens for $499 per month through GoodRx's platform. The partnership aims to target patients without adequate insurance coverage for these high-demand diabetes and weight-loss medications.

GoodRx Holdings Inc. (GDRX) shares jumped 5.08% in after-hours trading on Monday after announcing a collaboration with Novo Nordisk A/S to offer discounted GLP-1 medications at fixed pricing nationwide. Eligible self-paying patients can access all strengths of Ozempic and Wegovy pens for $499 per month through GoodRx's platform. The partnership aims to target patients without adequate insurance coverage for these high-demand diabetes and weight-loss medications [1].

The discount program operates across over 70,000 retail pharmacies nationwide, targeting patients without adequate insurance coverage for these high-demand diabetes and weight-loss medications. GoodRx research indicates that nearly 17 million people visited the platform seeking GLP-1 medication savings in the past year, representing a 22% increase from the previous period [2].

The collaboration marks the first time Ozempic has been available at this self-pay price point. This move comes as telehealth and digital health platforms are increasingly viewed as ways to provide greater access to in-demand products. The announcement follows similar pricing strategies from competitors. Eli Lilly and Co. (LLY) launched $499 monthly pricing for Zepbound’s highest doses through LillyDirect in July, while Novo Nordisk previously introduced NovoCare Pharmacy in March, offering direct-to-patient Wegovy delivery at the same price point [2].

The FDA's recent approval of an additional Wegovy indication for liver condition treatment further expands the addressable patient population. This approval may boost demand for GLP-1 medications, potentially benefiting GoodRx's new partnership [2].

GoodRx's stock closed regular trading at $5.12, up 37.27% for the session on Monday. The stock’s 52-week range spans $3.31-$8.80, with a current market capitalization of $1.78 billion and a price-to-earnings ratio of 55.27. The average daily volume of the healthtech stands at 1.56 million shares [3].

References:
[1] https://finance.yahoo.com/news/goodrx-stock-soars-after-striking-deal-to-sell-novo-nordisks-glp-1s-for-499month-130021070.html
[2] https://www.inkl.com/news/goodrx-holdings-surges-5-after-hours-on-novo-nordisk-partnership-for-499-monthly-ozempic-wegovy-access
[3] https://www.benzinga.com/markets/equities/25/08/47201182/goodrx-holdings-surges-5-after-hours-on-novo-nordisk-partnership-for-499-monthly-ozempic-wegovy-access